Citation Impact
Citing Papers
Macrophages Mediate Inflammation-Enhanced Metastasis of Ovarian Tumors in Mice
2007
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
2015
Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c- MYC transcription
2002 Standout
Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin™
2004
A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension
2019 StandoutNobel
Interaction of Hydroxylated Collagen IV with the von Hippel-Lindau Tumor Suppressor
2007 StandoutNobel
A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer
2006
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Epithelial‐mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients
2014
Hallmarks of Cancer: The Next Generation
2011 Standout
Adding pharmacogenomics to the development of new marine-derived anticancer agents
2006
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Chemokine Networks and Breast Cancer Metastasis
2007
Yondelis® (trabectedin, ET-743): the development of an anticancer agent of marine origin
2003
Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies
2003
Chemosensitivity linked to p73 function
2003 StandoutNobel
Drugs from the deep: marine natural products as drug candidates
2003 Standout
Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action
2002
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
2001
Iridium‐Catalyzed Asymmetric Intramolecular Allylic Amidation: Enantioselective Synthesis of Chiral Tetrahydroisoquinolines and Saturated Nitrogen Heterocycles
2011 StandoutNobel
Cytotoxic halogenoacrylic derivatives of distamycin A
2000
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
2006
DNA and its associated processes as targets for cancer therapy
2002
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
2008 StandoutNobel
VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia
2005
Ovarian cancer
2014 Standout
Value of Histopathology in Predicting Microsatellite Instability in Hereditary Nonpolyposis Colorectal Cancer and Sporadic Colorectal Cancer
2003
Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: Contrasting, overlapping and compensatory functions
2009
RAS oncogenes: weaving a tumorigenic web
2011
RNA-based recognition and targeting: sowing the seeds of specificity
2017 StandoutNobel
Drug discovery from natural sources
2006
Drug development from marine natural products
2008 Standout
Trabectedin
2007
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Marine pharmacology in 2000: Antitumor and cytotoxic compounds
2003
Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature
2015
JNK activation is critical for Aplidin™-induced apoptosis
2004
Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer
2007
Soft-Tissue Sarcomas in Adults
2005 Standout
Colorectal cancer
2013 Standout
Methylation of the RASSF1A Gene in Human Cancers
2002
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
2001
Cytotoxic α-bromoacrylic derivatives of distamycin analogues modified at the amidino moiety
2000
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
2007 Standout
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Plitidepsin Has a Dual Effect Inhibiting Cell Cycle and Inducing Apoptosis via Rac1/c-Jun NH2-Terminal Kinase Activation in Human Melanoma Cells
2007
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
2011 Standout
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
2017 StandoutNobel
Colorectal cancer
2019 Standout
Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis
2015
Marine pharmacology in 2001–2: antitumour and cytotoxic compounds
2004
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
miRNA–target chimeras reveal miRNA 3′-end pairing as a major determinant of Argonaute target specificity
2015 StandoutNobel
Progress in the development and acquisition of anticancer agents from marine sources
2003
In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors
2002
Natural products in anticancer therapy
2001
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone
2010
The discovery of a new potential anticancer drug: a case history
2003
Cascade Reactions in Total Synthesis
2006 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
EMT: 2016
2016 Standout
Argonaute CLIP Defines a Deregulated miR-122-Bound Transcriptome that Correlates with Patient Survival in Human Liver Cancer
2017 StandoutNobel
Pharmaceutical development of anticancer agents derived from marine sources
2000
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer
2017 Standout
Macrophage plasticity and polarization: in vivo veritas
2012 Standout
Antiangiogenic activity of aplidine, a new agent of marine origin
2004
Hepatotoxicity and metabolism of trabectedin: a literature review
2005
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Natural products to drugs: natural product derived compounds in clinical trials
2005
Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer
2019
Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft
2005
Cancer-related inflammation
2008 StandoutNature
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
An amino-bisphosphonate targets MMP-9–expressing macrophages and angiogenesis to impair cervical carcinogenesis
2004
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
2007 StandoutNature
Preservation of Fertility in Patients with Cancer
2009 Standout
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
2006 Standout
Progress in the clinical development of new marine-derived anticancer compounds
2004
Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications
2015 StandoutNobel
Monofluorination of Organic Compounds: 10 Years of Innovation
2015 Standout
Marine Natural Products and Related Compounds in Clinical and Advanced Preclinical Trials
2004
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
2009 StandoutScience
Natural Product Synthesis Using Multicomponent Reaction Strategies
2009 Standout
Molecular Approaches to Discover Marine Natural Product Anticancer Leads – An Update from a Drug Discovery Group Collaboration
2003
Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails
2005
Nuclear Receptors and Lipid Physiology: Opening the X-Files
2001 StandoutScience
The Hitchhiker’s Guide to Flow Chemistry
2017 Standout
Preclinical and clinical results with the natural marine product ET-743
2003
Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.
2001
Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review
2015
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials
2004
Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
2000
Chemistry and Biology of the Tetrahydroisoquinoline Antitumor Antibiotics
2002 Standout
Asymmetric Synthesis of Isoquinoline Alkaloids
2004 Standout
Synthesis of Ecteinascidin ET-743 and Phthalascidin Pt-650 from Cyanosafracin B
2000
Characterization of a von Hippel Lindau Pathway Involved in Extracellular Matrix Remodeling, Cell Invasion, and Angiogenesis
2006
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
p53 family update: p73 and p63 develop their own identities.
2001 StandoutNobel
Aplidine: A Paradigm of how to Handle the Activity and Toxicity of a Novel Marine Anticancer Poison
2007
Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.
2003
Mechanisms of cellular injury: potential sources of oxygen free radicals in ischemia/reperfusion.
1990
Halogenation of 1,1-diaryl alkenes
2010
Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion
2008
Phospholipase A2Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention
2011 Standout
In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells
2003
A Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients with Gastrointestinal Stromal Tumors
2002
miR‐181a mediates TGF ‐β‐induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer
2014
Therapeutic impact of ET-743 (Yondelis; trabectidin), a new marine-derived compound, in sarcoma
2003
Increased DNA Binding Specificity for Antitumor Ecteinascidin 743 through Protein−DNA Interactions?
2000
Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.
2001
Extracellular microRNAs in human circulation are associated with miRISC complexes that are accessible to anti-AGO2 antibody and can bind target mimic oligonucleotides
2020 StandoutNobel
Synthesis and Evaluation of Bishydroquinone Derivatives of (−)-Saframycin A: Identification of a Versatile Molecular Template Imparting Potent Antiproliferative Activity
2001
Works of Sergio Marchini being referenced
Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer.
1999
Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents
1999
microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial–mesenchymal transition
2014
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer
2012
Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4
2003
The soluble glycoprotein NMB (GPNMB) produced by macrophages induces cancer stemness and metastasis via CD44 and IL-33
2020
A Specific miRNA Signature Correlates With Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
2011
α-Bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity
1999
Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743
2004
Effect of Aplidin in acute lymphoblastic leukaemia cells
2003
Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent.
2001
Cytotoxic α-Halogenoacrylic Derivatives of Distamycin A and Congeners
2004
Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
2002
Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy
2005
Sequence-specific DNA alkylation of novel tallimustine derivatives.
1998
Brostallicin: a new concept in minor groove DNA binder development
2004
Unique Features of the Mode of Action of ET-743
2002
Mode of action of trabectedin in myxoid liposarcomas
2013
Analysis of Differential miRNA Expression in Primary Tumor and Stroma of Colorectal Cancer Patients
2014
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
2000
4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms.
2001
P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line.
2001
Changes in gene expression profile induced by the anticancer agent Aplidine in Molt-4 leukemic cell lines.
2003
Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.
2003